| Cost-of-illness studies: an updated review of current methods E Onukwugha, J McRae, A Kravetz, S Varga, R Khairnar, CD Mullins PharmacoEconomics 34 (1), 43-58, 2016 | 106 | 2016 |
| Hospitalization rates during potentially inappropriate medication use in a large population‐based cohort of older adults S Varga, M Alcusky, SW Keith, SE Hegarty, S Del Canale, M Lombardi, ... British journal of clinical pharmacology 83 (11), 2572-2580, 2017 | 51 | 2017 |
| The status of human papillomavirus vaccination recommendation, funding, and coverage in WHO Europe countries (2018–2019) P Bonanni, P Faivre, PL Lopalco, EA Joura, T Bergroth, S Varga, ... Expert Review of Vaccines 19 (11), 1073-1083, 2020 | 35 | 2020 |
| The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study KF Simacek, JJ Ko, D Moreton, S Varga, K Johnson, BJ Katic Journal of medical Internet research 20 (10), 2018 | 35 | 2018 |
| A review of US drug costs relevant to medicare, medicaid, and commercial insurers post-affordable care act enactment, 2010–2016 J McRae, FR Vogenberg, SW Beaty, E Mearns, S Varga, L Pizzi Pharmacoeconomics 35 (2), 215-223, 2017 | 20 | 2017 |
| The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting … LH Hua, CM Hersh, P Morten, J Kusel, F Lin, J Cave, S Varga, V Herrera, ... Journal of managed care & specialty pharmacy 25 (4), 490-498, 2019 | 17 | 2019 |
| Evaluating oncology value-based frameworks in the US Marketplace and challenges in real-world application: a multiple myeloma test case LM Djatche, JA Goble, G Chun, S Varga Journal of managed care & specialty pharmacy 24 (1), 39-46, 2018 | 13 | 2018 |
| Variation in hospital utilization at the end of life for patients with cancer in the Emilia-Romagna region of Italy DZ Louis, SE Hegarty, M Leoni, R De Palma, S Varga, R Melotti Tumori Journal 102 (6), 614-620, 2016 | 11 | 2016 |
| Cost-effectiveness of aspirin adherence for secondary prevention of cardiovascular events LM Djatche, S Varga, RD Lieberthal PharmacoEconomics-open, 1-10, 2018 | 9 | 2018 |
| Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent human papillomavirus vaccine in Belgium S Simoens, A Bento-Abreu, B Merckx, S Joubert, S Vermeersch, ... Frontiers in Pharmacology 12, 628434, 2021 | 8 | 2021 |
| Global burden of HPV-related cancers in men: A systematic literature review. S Varga, X Wang, K Luttropp, E Morais, A Walia, L Pimpin, J Eriksson, ... Journal of Clinical Oncology 37 (15_suppl), e13108-e13108, 2019 | 6 | 2019 |
| Preference and frequency of mobile phone App use for drug information among student pharmacists SK Park, MC Purnell, MK Freeman, RV Reese, S Varga Journal of Pharmacy Technology 33 (3), 87-95, 2017 | 6 | 2017 |
| Healthcare utilization and associated costs following initiation of perampanel in patients with epilepsy CL Morgan, S Varga, W Tsong, S Jenkins-Jones, S Holden Epilepsy & Behavior 110, 107137, 2020 | 2 | 2020 |
| The economic implications of non-adherence to aspirin in patients with prior primary cardiovascular events RD Lieberthal, S Varga, S Adams, M McCarey, B Toroni, D Whellan Circulation 134 (suppl_1), A13150-A13150, 2016 | 2 | 2016 |
| Disease-modifying therapy access issues and their impact on multiple sclerosis patients: An online mixed methods study J Ko, B Katic, K Simacek, D Moreton, N Buechler, S Varga | 2 | |
| Lack of clinician knowledge of human papillomavirus (HPV) vaccination to prevent HPV-related cancers in men: An interview study. S Varga, SG May, E Morais, A Shrestha, C Huber, A Tantri, M Roach, ... Journal of Clinical Oncology, 2019 | 1 | 2019 |
| Patient and provider characteristics associated with optimal post-fracture osteoporosis management NN Boytsov, AG Crawford, LA Hazel-Fernandez, JF McAna, R Nair, ... American Journal of Medical Quality 32 (6), 644-654, 2017 | 1 | 2017 |
| LONG-TERM COST-EFFECTIVENESS OF ADHERENCE TO ASPIRIN FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS L Djatche, S Varga, R Liebertal VALUE IN HEALTH 20 (5), A9-A9, 2017 | 1 | 2017 |
| Multiple sclerosis patient experiences with access to disease-modifying therapies: A qualitative analysis on the patient impact of medication access barriers (P3. 333) K Simacek, J Ko, S Varga, N Buechler, D Moreton, B Katic Neurology 88 (16 Supplement), P3. 333, 2017 | 1 | 2017 |
| Improving the patient-centered medical home (PCMH) evaluation process is essential to foster the PCMH movement S Varga, M Lombardi, V Maio Population health management 20 (1), 1-2, 2017 | 1 | 2017 |
